Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Radiation Oncology
Her2+
Questions discussed in this category
What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?
How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?
1 Answer available
In which Her2+ breast cancer patients would you recommend extended adjuvant therapy with neratinib?
The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.
1 Answer available
3144
2217
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Related Topics in Radiation Oncology
Lung Cancer
Workload
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers